The pharmaceutical landscape shifted dramatically when the FDA approved the first gut microbiome drug in late 2022. This wasn't your typical chemical compound or synthetic molecule—it was something entirely different.
The landscape of genetic medicine is undergoing a seismic shift, powered by the advent of CRISPR 3.0 technologies. This next generation of gene editing tools promises not just treatment, but